Monte Rosa Therapeutics, Inc. Common Stock (GLUE) Stock
Key stats
- Market cap
- $880.99M
- Price / Earnings ratio
- -6.9x
- EPS (TTM)
- -$1.40
- Volume
- Loading
- 52-week high
- $25.77
- 52-week low
- $9.68
Source: third-party data provider, as of November 13, 2026
Compare with GLUE
Recent news

Wall Street Analysts See a 152.87% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?
Wall Street Analysts See a 152.87% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?
GLUE

Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
GLUE

Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study
Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study
GLUE

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
GLUE
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 41.89
- MACD 12/26/9
- -0.28
- EMA 9 of MACD
- -0.34
- MACD histogram
- 0.06
- SMA 50
- $11.50
- Price below SMA 50
- EMA 50
- $11.86
- Price below EMA 50
- SMA 200
- $16.86
- Price below SMA 200
- EMA 200
- $15.67
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Wall Street Analysts See a 152.87% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?
Wall Street Analysts See a 152.87% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?
GLUE

Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
GLUE

Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study
Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study
GLUE

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
GLUE

BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
GLUE

Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
GLUE

Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise
GLUE

Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates
GLUE

Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
GLUE

3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher
3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher
GLUE
News tone: automated (AI) classification of the article's content, not a price prediction.
About Monte Rosa Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Markus Warmuth M.D. | President, CEO & Director | 1971 |
| Ms. Jennifer Champoux | Chief Operating Officer | 1972 |
| Mr. Philip Nickson J.D., Ph.D. | Chief Business & Legal Officer | 1979 |
| Mr. Filip Janku M.D., Ph.D. | Chief Medical Officer | 1974 |
| Mr. Matthew Bowen | Corporate Controller & Principal Accounting Officer | 1989 |
| Mr. Magnus Walter DPHIL | Chief Technology Officer | — |
| Dr. John C. Castle Ph.D. | Chief Data & Information Officer | 1971 |
| Dr. Sharon Townson Ph.D. | Chief Scientific Officer | 1975 |
| Mr. Andrew Funderburk | Chief Investor Relations and Strategy Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 41.89
- MACD 12/26/9
- -0.28
- EMA 9 of MACD
- -0.34
- MACD histogram
- 0.06
- SMA 50
- $11.50
- Price below SMA 50
- EMA 50
- $11.86
- Price below EMA 50
- SMA 200
- $16.86
- Price below SMA 200
- EMA 200
- $15.67
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $19.00
- Average
- $24.80
- High
- $28.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -15.7 | +17.3 | ||||||||||
| 2022 | -38.0 | +8.1 | +4.5 | -26.0 | -35.2 | +33.7 | -10.3 | -6.6 | -1.3 | +21.7 | -6.1 | -14.4 |
| 2023 | -4.9 | -15.9 | +26.5 | -46.0 | +40.8 | -9.3 | +9.6 | -14.9 | -22.7 | -24.8 | -9.4 | +81.1 |
| 2024 | -7.2 | +27.9 | +11.9 | -25.5 | -30.6 | -6.0 | +14.7 | +41.2 | -8.9 | +60.4 | +16.4 | -32.1 |
| 2025 | -6.3 | -15.5 | -16.4 | +10.8 | -14.7 | +0.2 | +7.4 | +0.2 | +50.6 | +71.3 | +34.0 | -0.6 |
| 2026 | +34.0 | -15.0 | -11.1 | +11.5 | +4.8 | +23.0 | -31.2 | -9.4 | -16.6 | -4.4 | -3.0 |



